Skip to main content
Premium Trial:

Request an Annual Quote

ZyGem, Quanta BioSciences Ink OEM Pact

NEW YORK (GenomeWeb News) – ZyGem today said that it has entered into an agreement with Quanta BioSciences to incorporate its enzymatic RNA-extraction technology into Quanta's quantitative PCR reagent kits.

According to Charlottesville, Va.-based ZyGem, its enzymatic technology uses a single-tube process to provide complete extraction of RNA including smaller RNA molecules, such as non-coding RNA and microRNA, that are excluded by other extraction methods.
The technology delivers higher molecular weight RNA and more representative transcriptome profiles than other methods and is well-suited for complete gene expression and non-coding RNA analyses, the company added.

Quanta, based in Gaithersburg, Md., offers a comprehensive line of qPCR reagents including the qScript cDNA SuperMix and PerfeCTa SuperMixes for qPCR and multiplex qPCR. The company said that its reagents are used for gene expression, pathogen detection, and genetic analysis applications in a variety of industries, including pharmaceutical research and development, diagnostics, agribusiness, and biodefense.

"In our testing, ZyGem's technology rapidly produced high-quality RNA, and we believe our customers will welcome the opportunity to obtain these benefits in their own work," David Schuster, director of R&D at Quanta, said in a statement.

Financial terms of the agreement were not disclosed.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.